This study reports improvements in the nutritional value of pork by including linseed in the diets of boar and gilt pigs. Two feeding strategies, either short-term or long-term, were employed: (i) 0 g or 114 g linseed per kg of food provided to 16 pigs of 87 kg live weight for 20 or 27 days; (ii) 0 g, 10 g, 20 g or 30 g linseed per kg of food provided to 64 pigs of 46 kg live weight for 54, 62, 68 or 75 days. All diets were supplemented with DL-α-tocopheryl acetate (0•2 g/kg). The 18 : 3n-3 contents (18 : 2n-6 :18 : 3n-3 ratios in parentheses) of the short-term 0 g and 114 g/kg, and long-term 0g, 10 g, 20 g and 30 g/kg linseed diets, were 2•1 g (7•75), 28•1 g (0•70), 1•0 g (8•86), 3•4 g (2•73), 6•0 g (1•66) and 8•1 g/kg food (1•25) respectively. The long-term 30 g/kg diet reduced the n-6 : n-3 ratio of muscle and adipose tissue as successfully as the short-term 114 g/kg diet to accord with guidelines for the overall human diet (5 :1 or less) but required only 0•73 as much linseed and increased the proportion of C20-22 n-3 fatty acids more effectively; compared with their respective control diets, the 114 g/kg and 30 g/kg diets more than halved the n-6 : n-3 ratios in muscle to 3•8 and 3•9, approximately trebled the concentrations of 18 : 3n-3 in muscle to 0•43 mg and 0•28 mg/g tissue, and doubled the concentrations of 20: 5n-3 in muscle to 0•08 mg and 0•10 mg/g tissue. Similar changes occurred in adipose tissue. With both strategies, the majority of the changes had occurred by the time the first groups were slaughtered. There was a strong relationship between the 18 : 2n-6 :18 : 3n-3 ratio of the food and tissues and the accumulation of all C20-22 n-3 fatty acids, except 22 : 6n-3, which was unaffected by dietary linseed. The improvements in nutritional value were obtained without changes in organoleptic characteristics, as measured by a trained taste panel, or significant loss of shelf-life, as measured by TBARS analysis and colour stability.

ROLLIS is an easily learnt, safe and effective alternative technique to standard HWL.

1518 Introduction: Haemophilia A is a rare inherited bleeding disorder characterised by spontaneous or trauma-related bleeding, most commonly into the joints, leading to pain, swelling and limited movement. Some 30–50% of patients with haemophilia A develop inhibitors to their standard treatment, comprised of FVIII concentrates. There are two bypassing agents used for the management of bleeding episodes in patients with haemophilia A with inhibitors in the UK: recombinant factor VII (rFVIIa, NovoSeven®) and plasma-derived activated prothrombin complex concentrate (pd-aPCC, Feiba®). Objective: A systematic review of the cost-effectiveness of pd-aPCC versus rFVIIa was published in 2003. Since the analysis, costs of bypassing agents in the UK have changed significantly (pd-aPCC +30% from ≤0.57/U to ≤0.74/U; rFVIIa -11% from ≤0.51/mcg to ≤0.46/mcg). The present study examines the evolution in costs of resolving a mild to moderate bleeding episode with treatment initiated outside hospital. Methods: A decision analytic model estimated the expected costs and outcomes of resolving a mild-moderate bleeding episode in patients with haemophilia A with inhibitors. The model compared three treatment regimens in patients with a mean weight 70kg. Each regimen comprised first-, second- and third-line treatment: (1) pd-aPCC-pd-aPCC-rFVIIa; (2) pd-aPCC-rFVIIa-rFVIIa; and (3) rFVIIa-rFVIIa-rFVIIa. Efficacy and dosing of pd-aPCC and rFVIIa were estimated from the published literature, with rFVIIa assumed to resolve 92% of mild-moderate bleeds when used as first and second line treatment and pd-aPCC resolving 79% and 88% of mild-moderate bleeds when used first and second line respectively. Patients whose bleeding episodes were not resolved with first-line treatment were admitted to hospital for second- and third-line treatment. Costs included in the economic model were bypassing agent costs and hospitalisation costs. Results: The different treatment regimens result in different total costs for the resolution of a single mild-moderate bleeding episode with up to three lines of treatment: (1) GBP 13,542 (EUR 15,180); (2) GBP 12,985 (EUR 14,556); and (3) GBP 8,569 (EUR 9,605). Since 2001, the costs of regimens 1 and 2 have increased by 26% and 18%, but regimen 3 has decreased by 11% in the UK. Conclusion: Divergence in the price of pd-aPCC and rFVIIa since 2001 has increased the cost-effectiveness of rFVIIa. The results reinforce the fact that effective first-line treatment with rFVIIa results in lower overall treatment costs due to a reduced need for further treatment and associated hospitalisation costs. Adopting rFVIIa as first-line treatment is cost-saving and more effective compared to reserving rFVIIa as a second- or third-line treatment option. Disclosures: Sewpaul: Novo Nordisk : Employment. Ashley:Novo Nordisk : Employment. Riley:Novo Nordisk Ltd: Employment.